This chapter addresses some of the issues pertaining to skeletal manifestations of hematopoietic tumors, especially when they present as primary tumors in bone. In such instances, a bone pathologist or even a general pathologist, rather than a hematopathologist, is more…
In the early 1920s, James Ewing identified a peculiar round-cell tumor that he called diffuse endothelioma of bone. The tumor predominantly affected the long tubular bones of young patients. This lesion was distinguished from the general category of unclassified round-cell…
Giant cell lesions form a group of entities with diverse clinical presentations and behaviors unified by the presence of a prominent population of multinucleated giant cells. They have been, by convention, divided into two major groups: those that were considered…
Nonossifying Fibroma (Fibrous Cortical Defect) Definition The terms nonossifying fibroma (nonosteogenic fibroma), fibrous cortical defect, and metaphyseal fibrous defect have been applied to the same metaphyseal fibrohistiocytic process. The location of the lesion in the growing portions of long tubular…
Fibrous Dysplasia This disorder was recognized as a clinical syndrome of disseminated skeletal deformities long before it was given the name fibrous dysplasia by Lichtenstein and Jaffe in two classic publications that appeared in 1938 and 1942. In older literature,…
Chondrosarcoma is the second most frequent primary malignant tumor of bone. It represents one fourth of all primary bone sarcomas. The term chondrosarcoma is used to describe a heterogeneous group of lesions with diverse morphologic features and clinical behavior. The…
Traditionally, cartilage lesions are considered to be of neoplastic, dysplastic, hamartomatous, and reactive origin. Reactive cartilage containing lesions are described in Chapters 20 and 23 . Enchondroma is an example of a benign cartilage neoplasm that most frequently occurs within…
Osteosarcoma is the most common primary malignant tumor of bone. When all aspects of its presentation are taken into consideration, it is evident that this term is used to describe a heterogeneous group of lesions with diverse morphology and clinical…
Benign osteoblastic tumors were first recognized as a distinct group by Jaffe and Mayer in 1932. The identification of osteoid osteoma as a separate entity came later in a 1935 report by Jaffe. Once osteoid osteoma had been established as…
During the past two decades, our knowledge of the molecular events that are responsible for the development and progression of many human neoplasms, including those that affect the skeleton, has dramatically improved. This has been made possible by numerous technologic…